SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, Phase II trial studying the combination of mocetinostat
and gemcitabine in patients who have previously demonstrated disease progression either
while, or within six months after, receiving chemotherapy with a gemcitabine-based regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration